Skip to main content

Table 4 Bleeding locations

From: Application of prothrombin complex concentrate for reversal of direct oral anticoagulants in clinical practice: indications, patient characteristics and clinical outcomes compared to reversal of vitamin K antagonists

  Total (n = 346) DOAC (n = 74) Vitamin K antagonist (n = 272) p
Intracranial 213 (61.6) 45 (60.8) 168 (61.8) 0.881
Upper/lower gastrointestinal 38 (11.0) 24 (18.9) 14 (8.8) 0.014
Superficial 22 (6.4) 4 (5.4) 18 (6.6) 0.705
Extremity 17 (4.9) 2 (2.7) 15 (5.5) 0.321
Abdominal 13 (3.8) 2 (2.7) 11 (4.0) 0.591
Thorax 11 (3.2) 4 (5.4) 7 (2.6) 0.218
Eye 6 (1.7) 1 (1.4) 5 (1.8) 0.776
Retroperitoneal 5 (1.4) 1 (1.4) 4 (1.5) 0.939
Haematuria 3 (0.9) 1 (1.4) 2 (0.7) 0.612
Epistaxis 2 (0.6) 0 (0.0) 2 (0.7) 0.459
Oral 1 (0.3) 0 (0.0) 1 (0.4) 0.601
  1. Abbreviation: DOAC direct oral anticoagulants